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See Article, pages 1325–1331Survival after either resection or liver transplantation for
hepatocellular carcinoma (HCC) is related intimately to tumour
recurrence. To reduce that risk, patients are selected for liver
transplantation currently on the basis of tumour size and number,
which are both crude, indirect measures of tumour biology.
Despite careful radiological assessment, often based on multiple
modalities and further review whilst on the waiting list, recur-
rence rates remain at 10–20%, even in the best centres [1]. A crit-
ical view of transplanting patients with such a high risk of tumour
recurrence might conclude that this was wasteful in an era of
extreme shortage of donor organs and a vital area for research
focused on improved recipient selection. The much higher rate
of HCC ‘recurrence’ after liver resection in patients with cirrhosis
(as high as 70% after 5 years) [2], almost certainly reﬂects the
combination of new primary tumour evolution as well as recur-
rence of the original tumour.
The pathological feature associated most closely with HCC
recurrence is vascular invasion, divided conventionally into mac-
roscopic (invasion of large blood vessels identiﬁed radiologically)
or microscopic, by deﬁnition a histological diagnosis. A targeted
biopsy of the lesion prior to resection or transplantation could
help determine the value of subsequent surgery if vascular inva-
sion was observed, thereby reducing futile transplantation. There
are caveats: the hallmark lesion of microscopic vascular invasion
is patchy and can be missed while a targeted biopsy may be dif-
ﬁcult technically and there may be multiple lesions. Moreover,
the risk of tumour tracking down the biopsy needle track is often
cited as a reason not to perform a pre-treatment staging biopsy.
That is not a view we share and published series (likely to esti-
mate risk to be at the higher end of the spectrum) reveal a low
risk of needle-track seeding, up to 2.7% overall [3,4].
Microscopic vascular invasion can only be conﬁrmed as deﬁ-
nitely present or absent when the whole tumour is available for
careful histological examination after surgery. Thus, there is a
real need for surrogate markers of vascular invasion in HCC that
can be determined before resection or liver transplantation. Such
a marker would have a profound effect on clinical practice, allow-
ing patients with larger tumours without vascular invasionJournal of Hepatology 20
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or selection of patients with early-stage but more aggressive dis-
ease for clinical trials of new adjuvant agents, whilst avoiding
futile surgery or liver transplantation, with implications for the
restricted donor pool.
Minguez et al., [5] in the current issue of the Journal, address
this important question using genome-wide gene expression
microarrays to derive a gene expression signature associated with
macroscopic and microscopic vascular invasion. The authors used
fresh-frozen tissue from 79 patients with hepatitis C virus related
HCC as a ‘training set’ to deﬁne the ‘vascular invasion signature’,
which comprised 14 genes that were over-expressed and 21 genes
that were under-expressed in HCC with vascular invasion com-
pared to HCC without vascular invasion. The ‘vascular invasion
signature’ was then validated using formalin ﬁxed parafﬁn
embedded tissue in a further set of 135 patients with HCC and var-
ious causes of liver injury including hepatitis B virus and alcohol
as well as those with hepatitis C virus infection. The ‘vascular
invasion signature’ identiﬁed the presence or absence of vascular
invasion in the validation set correctly in 69%. Following univari-
ate andmultivariate logistic regression analyses, both tumour size
and the ‘vascular invasion signature’ were associated indepen-
dently with vascular invasion, while ROC analysis showed that
the ‘vascular invasion signature’ in combination with tumour size
improved the sensitivity for the prediction of vascular invasion,
but had little additive beneﬁt over size alone in identiﬁcation of
those without vascular invasion (their Supplementary Table 1).
Their study has several limitations. Firstly, there are differ-
ences in the methods used for the training and validation sets.
The training set used fresh-frozen tissues on the Affymetrix
U133Plus2.0 array, containing probes from >50,000 transcripts
and the validation set used formalin-ﬁxed, parafﬁn embedded
tissues in the Illumina DASL assay, covering 29,000 genes. The
platforms use different probe sets, which are unlikely to be
directly comparable; arguably, this is also a strength of the study,
since successful validation of the ‘vascular invasion signature’
with a different platform suggests that the results are more appli-
cable generally. However, gene expression proﬁles are inﬂuenced
by mRNA quality and that extracted from formalin-ﬁxed, parafﬁn
embedded tissue is generally more degraded and of lower quality
than that extracted from fresh frozen tissue. Nevertheless, a num-
ber of studies suggest equivalent gene expression proﬁles can be
obtained using fresh-frozen or formalin-ﬁxed, parafﬁn embedded
tissue on the same platform, but in this study design the use of11 vol. 55 j 1174–1175
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different tissue preservation methods on different platforms
might have introduced bias.
Secondly, there are a number of important clinical differences
between the training and validation groups. All the patients in
the training set with HCC had HCV-related HCC, while in contrast
the validation set had HCC with liver disease of mixed aetiology.
While the validation set better reﬂects the ‘real world’, the single
aetiology of the training setmight havemissed some genes impor-
tant for prognosis of non-HCV-related HCC. Perhaps more impor-
tantly, all 8 cases with macroscopic vascular invasion were in
the training set. The heatmap (their Fig. 1) shows a dominant effect
of these cases on the gene signature. Thus, gene expression proﬁles
ofmacroscopic vascular invasion appear to have a strong inﬂuence
on the genes selected for the signature, which appears less consis-
tent among the group with microscopic vascular invasion, which
of course has clinical implications for tumour recurrence.
Finally, the follow-up period for the training set is much
shorter than the validation set (median 21 months vs.
34 months), thus there are likely to be more individuals in the
training set yet to develop HCC recurrence but allocated currently
to the ‘wrong’ group.
Microscopic vascular invasion, which cannot be determined
readily or reliably before surgery, is such an important risk factor
for the long-term outcome that many previous studies have
sought to identify tumour derived molecular markers to predict
vascular invasion and the risk of tumour recurrence (reviewed in
[6]). The ideal marker would be easy to measure, reproducible
and have high negative and positive predictive value for vascular
invasion inHCCarising on a background of liver disease of any aeti-
ology. Candidate markers so far range from cell cycle regulators,
oncogenes, tumour suppressors, angiogenesis,markers of chromo-
some instability [6], and more recently, microRNA expression [7].
Rationally, a gene expression signature is a strong candidate as it
reﬂects global phenotypic change in a complex genetic disease
such as HCC and indeed, previous studies have also proposed gene
signatures that are related to vascular invasion [8–14]. However,
this studyhighlights the limited reproducibility of gene expression
microarrays between different platforms, centres and populations,
as two of the gene signatures identiﬁed previously in different lab-
oratories [8,9] were tested in the current cohort and were not pre-
dictive of vascular invasion in their hands. This question has been
further addressed by the same group in a separate study [15]
assessing the concordance of 22 published gene expression signa-
tures. The current ‘vascular invasion signature’ clustered with a
number of poor prognosis gene expression signatures [15].
The use of tumour gene expression to predict vascular invasion
still requires a targeted pre-operative biopsy, just as conventional
histological assessment of microvascular invasion and exactly the
same caveats apply. Comparison of conventional histological
assessment and tumour related gene signatures from the same
sample could be instructive. The authors address the risks associ-
ated with a targeted biopsy and conclude that this approach is
safe and on balance, it is a risk that would be outweighed if the
biopsy ﬁndings were to improve patient selection for liver resec-
tion or liver transplantation. However, this and other studies
investigating molecular markers have deﬁned molecular markers
in resection specimens. It remains to be shown that anymolecular
marker determined in a pre-operative biopsy correlates sufﬁ-
ciently well with the same marker in the surgical specimen.
An accurate circulating marker for microscopic vascular inva-
sion would be even better than a tissue marker as this wouldJournal of Hepatology 2011obviate the need for a pre-operative biopsy. Traditional serum
markers, such as alphafetoprotein, have limitations. Novel mark-
ers such as circulating tumour cells, circulating microRNA or
serum proteomic proﬁle, are areas of active research and may
provide predictive markers in the future.
In conclusion, this study has deﬁned a gene expression signa-
ture that correlates well with vascular invasion in resected HCC
samples, but there is a long way to go before we have an accurate
surrogate marker of vascular invasion, available before surgery,
that could be introduced into clinical practice.Conﬂict of interest
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